Influenza A virus H1N1 vaccine intranasal - BioDiem/Serum Institute of India

Drug Profile

Influenza A virus H1N1 vaccine intranasal - BioDiem/Serum Institute of India

Alternative Names: LAIV influenza A vaccine H1N1 - SII; Live-attenuated influenza virus vaccine H1N1; Nasovac; Pandemic influenza A H1N1 - intranasal

Latest Information Update: 04 Mar 2014

Price : $50

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer Serum Institute of India
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 31 Jul 2010 Launched for Influenza-A virus H1N1 subtype in India (Intranasal)
  • 10 Jul 2010 The Serum Institute of India completes a phase II/III trial in Influenza-A virus H1N1 (prevention, in paediatric, adult and elderly volunteers) in India
  • 10 Jul 2010 The Serum Institute of India completes a phase I trial in Influenza-A virus H1N1 (prevention, in volunteers) in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top